Theravance Biopharma (TBPH) Current Leases (2019 - 2026)

Theravance Biopharma (TBPH) has 8 years of Current Leases data on file, last reported at $10.8 million in Q1 2026.

• On a quarterly basis, Current Leases fell 0.51% year-over-year to $10.8 million in Q1 2026; TTM through Mar 2026 was $10.8 million, a 0.51% decrease from a year earlier, with the FY2025 full-year figure at $10.9 million, up 2.18% from the prior year.
• Current Leases for Q1 2026 stood at $10.8 million, down from $10.9 million in the prior quarter.
• Over the last five years, Current Leases for TBPH reached as high as $10.9 million in Q4 2025 and fell as low as $692000.0 in Q3 2022.
• Historically, Current Leases has averaged $7.2 million across 5 years, with a median of $7.4 million in 2023.
• Across the five-year window, Current Leases soared 1303.61% in 2023 and plunged 56.8% in 2024, its largest moves.
• Year by year, Current Leases stood at $6.8 million in 2022, then tumbled by 41.91% to $3.9 million in 2023, then jumped by 173.06% to $10.7 million in 2024, then gained by 2.18% to $10.9 million in 2025, then declined by 1.76% to $10.8 million in 2026.
• Per Business Quant data, the three most recent Current Leases figures were $10.8 million in Q1 2026, $10.9 million in Q4 2025, and $10.9 million in Q3 2025.